Author:
Zhao Yibei,Jiang Huiming,Xue Lifen,Zhou Mi,Zhao Xiaobing,Liu Fei,Jiang SongJiang,Huang Jing,Meng Long
Funder
Chongqing Science & Technology Commission
Publisher
Springer Science and Business Media LLC
Reference37 articles.
1. Couzin-Frankel J. Breakthrough of the year 2013. Cancer Immunother Sci. 2013;342(6165):1432–3.
2. Park J, Kwon M, Shin E-C. Immune checkpoint inhibitors for cancer treatment. Arch Pharm Res. 2016;39:1577–87.
3. Lee JB, Kim HR, Ha S-J. Immune checkpoint inhibitors in 10 years: contribution of basic research and clinical application in cancer immunotherapy. Immune Netw. 2022;22(1):e2.
4. Kaushik I, Ramachandran S, Zabel C, et al. The evolutionary legacy of immune checkpoint inhibitors. Semin Cancer Biol. 2022;86(Pt 2):491–8.
5. Hanson DC, Canniff PC, Primiano MJ, et al. Preclinical in vitro characterization of anti-CTLA4 therapeutic antibody CP-675,206. Cancer Res. 2004;64(7_Supplement):877.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献